The Efficacy of Dexamethasone Versus N-Acetylcysteine in Prevention of Post-Embolization Syndrome in Hepatocellular Carcinoma Patients: A Multicenter Randomized, Double-Blind, Double-Dummy, Non-Inferiority Trial.
Padungkeat Karasin, Kittithat Tantitanawat, Chanchai Charonpongsuntorn, Anuchit Suksamai, Sakkarin Chirapongsathorn
Asia Pac J Clin Oncol 10.1111/ajco.70127
摘要
摘要
BACKGROUND AND AIMS: Post-embolization syndrome (PES) is a frequent complication after hepatocellular carcinoma (HCC) treatment. This study compared dexamethasone (DEX) versus N-acetylcysteine (NAC) for efficacy and safety in preventing PES at 48 h after transcatheter arterial chemoembolization (TACE). METHODS: This Phase 3, randomized (1:1), double-blind, double-dummy, parallel-group, non-inferiority study, included patients with early- to intermediate-stage HCC (BCLC Stages A-B) without macrovascular invasion who were candidates for TACE. Participants were randomly assigned to receive either an intravenous single dose of 8 mg DEX or NAC as part of the periprocedural TACE protocol. RESULTS: A total of 85 patients were included in the outcome analysis. PES incidence was non-inferior between groups (difference proportion DEX-NAC 0.02, [95% CI: -0.13 to 0.17]). However, subgroup symptoms' analysis showed significantly greater reduction in abdominal pain (87.5% vs. 55.3%, p = 0.002) and fever (52.5% vs. 28.9%, p = 0.035) in DEX group compared to NAC group. Liver decompensation was significantly greater reduction in the DEX group than the NAC group (90% vs. 52.6%, p < 0.001). Anaphylactoid reactions (18.4%) were observed exclusively in the NAC group. Multivariate analysis showed preexisting high serum ALT was associated with an increased risk of developing PES (OR: 1.05; 95% CI: 1.01-1.08), and a higher chemotherapy dosage emerged as an independent risk factor for post-TACE liver decompensation (OR: 1.00; 95% CI: 0.84-0.99). CONCLUSION: PES incidence was non-inferior between groups. However, at 48 h post-TACE, the DEX regimen was associated with a significant reduction in fever, pain, and liver decompensation.
KM 提取结果
0 个 Figure · 0 个 KM 面板